$2.59 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 134 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -20,859 | -100.0% | -0.01% | – |
| RCPT | Exit | RECEPTOS INC | $0 | – | -2,000 | -100.0% | -0.01% | – |
| PRGO | Exit | PERRIGO CO PLC | $0 | – | -3,500 | -100.0% | -0.02% | – |
| IRWD | Exit | IRONWOOD PHARMACEUTICALS INC | $0 | – | -63,700 | -100.0% | -0.03% | – |
| IART | Exit | INTEGRA LIFESCIENCES HLDGS C | $0 | – | -59,468 | -100.0% | -0.13% | – |
| ZSPH | Exit | ZS PHARMA INC | $0 | – | -132,000 | -100.0% | -0.23% | – |
| STJ | Exit | ST JUDE MED INC | $0 | – | -107,719 | -100.0% | -0.26% | – |
| AMPH | Exit | AMPHASTAR PHARMACEUTICALS IN | $0 | – | -448,532 | -100.0% | -0.26% | – |
| DERM | Exit | DERMIRA INC | $0 | – | -496,387 | -100.0% | -0.29% | – |
| JUNO | Exit | JUNO THERAPEUTICS INC | $0 | – | -183,149 | -100.0% | -0.32% | – |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -2,505,872 | -100.0% | -0.34% | – |
| HUM | Exit | HUMANA INC | $0 | – | -75,500 | -100.0% | -0.48% | – |
| EXEL | Exit | EXELIXIS INCput | $0 | – | -4,000,000 | -100.0% | -0.50% | – |
| INSM | Exit | INSMED INC | $0 | – | -891,546 | -100.0% | -0.72% | – |
| BSX | Exit | BOSTON SCIENTIFIC CORP | $0 | – | -1,405,348 | -100.0% | -0.83% | – |
| INGN | Exit | INOGEN INC | $0 | – | -601,772 | -100.0% | -0.89% | – |
| ONCE | Exit | SPARK THERAPEUTICS INC | $0 | – | -631,192 | -100.0% | -1.27% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.